Zydus Cadila Gets Final Nod From USFDA To Market Generic Seizures Drug
Drug firm Zydus Cadila on Thursday said it has received final approval from the US health regulator to market generic Lamotrigine extended-release tablets, used to treat certain types of seizures.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Lamotrigine extended-release tablets USP in the strengths of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg, Zydus Cadila said in a statement.
The product will be manufactured at the group's manufacturing facility at special economic zone (SEZ), Ahmedabad, it added.
The group now has 283 approvals and has so far filed over 386 abbreviated new drug applications (ANDAs) since the commencement of its filing process, Zydus Cadila said.
Coutts Sets Scope On New Continent
Coutts steps into private marketsCoutts, the private bank best known for serving Britain’s wealthiest families and the... Read more
From Cypherpunk To Citadel
How Crypto Moved from the Wild West to the Mainstream Financial SystemA long-form analysis of Bitcoin's journey from fri... Read more
ACB Securities: Building Scale, Trust & Innovation
ACB Securities: Building Scale, Trust and Innovation in Vietnam’s Capital MarketsACB Securities (ACBS) is emerging as ... Read more
War Risk Returns To Markets As VIX Surges
For most of the past year, global markets behaved as though geopolitical risk had largely disappeared. Inflation was eas... Read more
Stablecoin The Future Of Currency?
The payments system is undergoing a quiet but consequential shift. What was once the exclusive preserve of central banks... Read more
BoE Loosens Capital Rules
The Bank of England has taken a significant step towards easing post-crisis regulation by lowering its estimate of the c... Read more